Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > Nanotechnology firm Liquidia lands $7M in financing

August 1st, 2009

Nanotechnology firm Liquidia lands $7M in financing

Abstract:
Nanotechnology firm Liquidia Technologies has closed on just a bit more than $7 million in new financing.

According to a filing with the Securities and Exchange Commission, Liquidia raised $7,031,130 in equity funding on July 15.

Neal Fowler, the company's chief executive officer, told the Triangle Business Journal that the new funds would be used for drug design and delivery.

Its first target is a vaccine, which Liquidia hopes to have in clinical trials by late 2010, the newspaper reported.

Several pharmaceutical firms have already licensed Liquidia technology for drug development, according to Fowler.

In January, Liquidia announced a partnership with Abbott to develop means of delivering drugs through nanotechnology..

Liquidia has developed a nanotechnology program called PRINT. The process uses nanotechnology to produce thin films that can be used for light management and other uses.

Source:
localtechwire.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Quantum computer improves AI predictions April 17th, 2026

Flexible sensor gains sensitivity under pressure April 17th, 2026

A reusable chip for particulate matter sensing April 17th, 2026

Detecting vibrational quantum beating in the predissociation dynamics of SF6 using time-resolved photoelectron spectroscopy April 17th, 2026

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

Nanomedicine

A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026

New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025

New imaging approach transforms study of bacterial biofilms August 8th, 2025

Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025

Announcements

A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026

Qjump: Shallow-circuit quantum sampling guides combinatorial optimization On up to 104 superconducting qubits, Qjump assists in searching the ground states of hard Ising problems and might outperform simulated annealing on near-term quantum hardware April 17th, 2026

Rice study resolves decades-old mystery in organic light-emitting crystals: Findings reveal how molecular defects can enhance light conversion efficiency: April 17th, 2026

UC Irvine physicists discover method to reverse ‘quantum scrambling’ : The work addresses the problem of information loss in quantum computing system April 17th, 2026

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project